CA
NZ
UK
AU
IND
US
Greenwich LifeSciences (NASDAQ: GLSI) reported that the European Medicines Agency has granted approval for its GP2 immunotherapy in the FLAMINGO-01 Phase III trial. The decision opens the pathway for up to approximately 200,000 doses to be administered across an expanded network of 170‑180 European …
MacroGenics Inc. (NASDAQ: MGNX) confirmed that a long‑standing board member will exit the organization later this year. Dr. Karen Ferrante, M.D. Communicated her decision to the board, establishing a clear timeline for the transition. The company emphasized that the departure is unrelated to any …
Seres Therapeutics, Inc. (NASDAQ: MCRB) held its 2026 Annual Meeting of Stockholders after reconvening from a June 9 adjournment caused by insufficient quorum. The gathering on July 8, 2026, served as a platform for several governance actions that could shape the biotech firm’s strategic …
In a notable corporate governance move, ResMed's CEO, Michael Farrell, has sold 4,991 shares of the company on July 9, under a pre-established 10b5-1 plan. This strategic action raises questions regarding potential shifts in investor confidence and may have cascading effects on the broader …
Virax Biolabs Group Ltd. Has seen a significant stock surge after a deal with Fosun, a development for investors in the healthcare sector. The company's stock rose in response to the news, with investors reacting to the partnership.
The situation is compounded by a strike from health workers demanding payment of overdue wages, threatening to further destabilize an already overwhelmed healthcare system. The dual challenges of rising infections and workforce disruptions pose risks not only to public health but also to sectors …
Kyverna Therapeutics, Inc. (NASDAQ: KYTX) disclosed that it has revised its $150.0 million loan agreement with Oxford Finance LLC and participating lenders. The amendment adjusts draw schedules, introduces new fees, and links future financing to specific performance milestones.
Vera Therapeutics disclosed a senior management change that reshapes its regulatory leadership. The filing details a transition of the chief regulatory function to a new executive while retaining the departing officer in an advisory capacity.
AstraZeneca's shares dropped 9% on Thursday after the company disclosed that a late‑stage trial of an experimental heart medication failed to achieve its primary endpoint. The announcement sent a ripple through European markets, prompting a sell‑off in other pharmaceutical stocks and weighing on the …
Forte Biosciences (NASDAQ: FBRX) has shared promising early-stage clinical data for its investigational treatment targeting vitiligo, a chronic autoimmune skin disorder characterized by depigmentation. The company’s lead candidate demonstrated encouraging outcomes in a recent trial, reinforcing its potential as a therapeutic option in a …
Please wait processing your request...